PT  - JOURNAL ARTICLE
AU  - Parashar, Kalind
AU  - Grant, Paul
AU  - Traylor, Katie
AU  - Patel, Malaykumar
AU  - Balon, Helena
AU  - Beauvais, Michele
AU  - Wong, Ching-yee
AU  - Rydberg, John
TI  - Complementary role of somatostatin receptor scintigraphy and FDG PET in the evaluation of neuroendocrine tumors
DP  - 2011 May 01
TA  - Journal of Nuclear Medicine
PG  - 1012--1012
VI  - 52
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/52/supplement_1/1012.short
4100  - http://jnm.snmjournals.org/content/52/supplement_1/1012.full
SO  - J Nucl Med2011 May 01; 52
AB  - 1012 Learning Objectives 1. Review imaging techniques and limitations of somatostatin receptor scintigraphy (SRS) 2. Present several examples of FDG and SRS imaging in the same patient with pathologic correlation. When evaluating the extent of neuroendocrine tumors (NETs), SRS is part of the standard workup. Although multiple promising agents are being researched, currently, In-111 pentetreotide and F-18 FDG are the only two radiopharmaceuticals approved in the USA for routine clinical imaging of NET’s. Since NETs are a heterogenous group of tumors of varying histological grades and with variable somatostatin receptor expression and density, pentetreotide may not always be the optimal radiopharmacologic imaging agent. We will present paired patient examples of low grade tumors better imaged with SRS SPECT/CT, as well as high grade tumors, whose extent was better imaged with FDG PET/CT. We will review considerations for SRS SPECT/CT versus FDG PET/CT and relate this to tumor pathology